Literature DB >> 15488762

APRIL promotes B-1 cell-associated neoplasm.

Lourdes Planelles1, Carla E Carvalho-Pinto, Gijs Hardenberg, Salette Smaniotto, Wilson Savino, Ruth Gómez-Caro, Melchor Alvarez-Mon, Joan de Jong, Eric Eldering, Carlos Martínez-A, Jan Paul Medema, Michael Hahne.   

Abstract

A tumor-supporting role for the TNF-like ligand APRIL has been suggested. Here we describe that 9- to 12-month-old APRIL transgenic mice develop lymphoid tumors that originate from expansion of the peritoneal B-1 B cell population. Aging APRIL transgenic mice develop progressive hyperplasia in mesenteric lymph nodes and Peyer's patches, disorganization of affected lymphoid tissues, mucosal and capsular infiltration, and eventual tumor cell infiltration into nonlymphoid tissues such as kidney and liver. We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488762     DOI: 10.1016/j.ccr.2004.08.033

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  36 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

2.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

3.  13q14 deletions in CLL involve cooperating tumor suppressors.

Authors:  Alexey Palamarchuk; Alexey Efanov; Natalya Nazaryan; Urmila Santanam; Hansjuerg Alder; Laura Rassenti; Thomas Kipps; Carlo M Croce; Yuri Pekarsky
Journal:  Blood       Date:  2010-01-13       Impact factor: 22.113

Review 4.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

Authors:  J L Vosters; N Roescher; G G Illei; J A Chiorini; P P Tak
Journal:  Oral Dis       Date:  2011-12-29       Impact factor: 3.511

6.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

Review 7.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

8.  B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.

Authors:  Stacey R Dillon; Brandon Harder; Kenneth B Lewis; Margaret D Moore; Hong Liu; Thomas R Bukowski; Nels B Hamacher; Megan M Lantry; Mark Maurer; Cecile M Krejsa; Jeff L Ellsworth; Susan Pederson; Keith B Elkon; Mark H Wener; Maria Dall'Era; Jane A Gross
Journal:  Arthritis Res Ther       Date:  2010-03-19       Impact factor: 5.156

9.  Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.

Authors:  Ana V Miletic; Amy N Anzelon-Mills; David M Mills; Sidne A Omori; Irene M Pedersen; Dong-Mi Shin; Jeffrey V Ravetch; Silvia Bolland; Herbert C Morse; Robert C Rickert
Journal:  J Exp Med       Date:  2010-10-18       Impact factor: 14.307

10.  Similarities and differences between selective and nonselective BAFF blockade in murine SLE.

Authors:  Meera Ramanujam; Xiaobo Wang; Weiqing Huang; Zheng Liu; Lena Schiffer; Haiou Tao; Daniel Frank; Jeffrey Rice; Betty Diamond; Karl O A Yu; Steven Porcelli; Anne Davidson
Journal:  J Clin Invest       Date:  2006-02-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.